Form: 8-K

Current report filing

July 1, 2004

Documents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (date of earliest event reported): July 1, 2004

 

 

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

 

Virginia   001-13467   56-1641133

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

601 Biotech Drive

Richmond, Virginia 23235

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (804) 648-3820

 

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.

 

On July 1, 2004, the registrant issued a press release relating to the completion of a new virology laboratory, the issuance of a patent and the initiation of the sale of a new bio-defense reagents product line. A copy of the press release is attached as an exhibit hereto.

 

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

 

(a) Financial statements of businesses acquired.

 

Not Applicable.

 

(b) Pro forma financial information.

 

Not Applicable.

 

(c) Exhibits.

 

  99.1 On July 1, 2004, the registrant issued a press release relating to the completion of a new virology laboratory, the issuance of a patent and the initiation of the sale of a new bio-defense reagents product line. A copy of the press release is attached as an exhibit hereto.

 

2

Pursuant to the requirement of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

COMMONWEALTH BIOTECHNOLOGIES, INC.
By:  

/s/ Robert B. Harris, Ph.D.
    Robert B. Harris, Ph.D.
    President and Chief Executive Officer

 

Dated: July 1, 2004

 

3

EXHIBIT INDEX

 

Number
  

Description of Exhibit
99.1   On July 1, 2004, the registrant issued a press release relating to the completion of a new virology laboratory, the issuance of a patent and the initiation of the sale of a new bio-defense reagents product line. A copy of the press release is attached as an exhibit hereto.

 

4